medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2020, Number 2

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2020; 36 (2)

Characterization of anti-HLA antibodies in Cuban possible receptors of heart transplant

Marcell RL, Morera BLM, Ustariz GCR, Ramírez HM, Nafeh Abi-rezk M, Chang MA

Language: Spanish
References: 17
Page: 1-13
PDF size: 386.89 Kb.


ABSTRACT

Introduction: In survival after heart transplantation, the use of antibodies against the main histocompatibility system (anti-HLA antibodies) is important. Six years ago, the percentage of anti-HLA antibodies against panel (PRA) by enzyme-linked immunosorbent assay (ELISA) method was introduced in Cuba as part of the pre-transplant compatibility tests of heart transplant recipients.
Objective: To characterize anti-HLA antibodies in Cuban heart transplant recipients.
Methods: Between September 2013 and April 2017, PRA by ELISA was performed on 38 patient samples received in the histocompatibility laboratory of the Institute of Hematology and Immunology. Comparison of proportions was used for statistical analysis.
Results: 47.4% of the study patients presented anti-HLA antibodies; those in class were the most frequent. The proportion of patients with PRA of 0% was higher in PRA class II than in class I (p=0.0027). The proportion of patients with PRA class I was greater, accounting for 20-75% (p=0.0046). 77.8% of the patients had a class I PRA greater than 10%, while in class II PRA it reached 80%.
Conclusions: The percentage of anti-HLA antibodies versus a panel of enzyme linked immunosorbent assay method allowed better characterization of anti-HLA antibodies, which contributed to improving compatibility in this type of patient.


REFERENCES

  1. Zamorano J, Sepúlveda L. Trasplante cardíaco. Rev Hosp Clín Univ Chile. 2007;18:299-309.

  2. Kittleson MM. Changing Role of Heart Transplantation. Heart Fail Clin. 2016;12(3):411-21.

  3. Romero Cabrera AJ. Insuficiencia cardiaca en el anciano. Un problema no resuelto. Medisur. 2004;2(1):72-85.

  4. 4 . Soler Morejón CD, Mesquia de Pedro N. Insuficiencia cardiaca: una causa importante de muerte. Rev Cub Med. 2014;53(4):359-62.

  5. 5 . Ministerio de Salud Pública. Anuario estadístico de salud 2018 [acceso 01/07/2020]. Disponible en: Disponible en: http://files.sld.cu/bvscuba/files/2019/04/Anuario-Electr%C3%B3nico-Espa%C3%B1ol-2018-ed-2019-compressed.pdf

  6. Velez M, Johnson MR. Management of allosensitized cardiac transplant candidates. Transplant Rev. 2009;23:235-47.

  7. Kobashigawa J MM, West L, Kerman R, George J, Rose M, Zeevi A, Reinsmoen N, Patel J, Reed EF. Report From a Consensus Conference on the Sensitized Patient Awaiting Heart Transplantation. J Heart Lung Transplant. 2009;28:213-25.

  8. Al-Mohaissen MA IA, Cheung A, Kaan A, Chiu W, Kealy J, Virani SA. A Successful 4S Heart Transplantation. Can J Cardiol. 2011;27:679-81.

  9. Barten MJ, Beiras-Fernandez A, Berchtold-Herz M, Boeken U, Garbade J, Hirt S, et al. The clinical impact of donorspecific antibodies in heart transplantation. Transplant Rev. 2018;32(4):207-17.

  10. Conway J, Dipchand AI. Challenges with sensitized recipients in pediatric heart transplantation. Clinics. 2014;69(S1):17-21.

  11. 11 . Reinsmoen NL, Mirocha J, Lai CH, Naim M, Ong G, Wang Q, et al. Optimizing transplantation of sensitized heart candidates using 4 antibody detection assays to prioritize the assignment of unacceptable antigens. J Heart Lung Transplant. 2016;35(2):165-72.

  12. 12 . Connor MJ, Pahl E, Webber SA, Rossano JW. Recent advances in heart transplant immunology: The role of antibodies. Progress in Pediatric Cardiology. 2016;43:81-5.

  13. 13 . Immucor GTI Diagnostics Inc. LIFECODES QuikScreen for in vitro diagnostic use(package insert); LIFECODES B-Screen for in vitro diagnostic use (package insert), Waukesha, WI; LIFECODES Quik-ID Class I for in vitro diagnostic use (package insert); LIFECODES Quik-ID Class II for in vitro diagnostic use (package insert). [accessed 15/08/2016]. Available from: Available from: http://www.immucor.com/global/Products/Pages/LIFECODES-Screen-Identification.aspx

  14. Schumacher KR RD, Kamoun M, Caruthers R, Gajarski RJ. HLA desensitization in pediatric heart transplant candidates: Efficacy of rituximab and IVIg. J Heart Lung Transplant. 2012;31(9):1041-2.

  15. Chang A, Marcell L, Ustariz CR, Bencomo A. Método cubano para determinar el porcentaje calculado de anticuerpos reactivos contra panel. Rev Cub Hematol Inmunol Hemoter. 2018;34(3):41-3.

  16. Rodey GE NJ, Whelchel JD, Revels KW, Bray RA. Epitope specificity of HLA class I alloantibodies. I. Frequency analysis of antibodies to private versus public specificities in potential transplant recipients. Hum Immunol. 1994;39(4):272-80.

  17. 17 . Marcell L, Ustariz CR, Costales DT, Chang A, Bencomo A Identificación de anticuerpos anti-HLA en pacientes en espera de trasplante renal. Rev Cub Hematol Inmunol Hemoter. 2015;31(2):138-49.




2020     |     www.medigraphic.com